| |
| |
|
| Insider
Information: |
Yu Tony |
| Relationship: |
|
| City: |
Westlake Village |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
10,869 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$36,194 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
10,869 |
|
|
| Total
Value |
$36,194 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Genelux Corp |
GNLX |
|
2024-06-24 |
10,869 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
24 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GNLX |
Genelux Corp |
VP, Clinical Trial OperationsO |
• – – |
2023-01-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
150,000 |
|
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
159,000 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-08-18 |
4 |
S |
$23.73 |
$77,478 |
D/D |
(3,265) |
155,735 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-08-30 |
4 |
S |
$24.70 |
$489,060 |
D/D |
(19,800) |
135,935 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-09-13 |
4 |
S |
$21.14 |
$629,927 |
D/D |
(29,800) |
106,135 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-09-15 |
4 |
AS |
$21.56 |
$227,630 |
D/D |
(10,400) |
106,135 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-09-15 |
4 |
OE |
$6.00 |
$62,400 |
D/D |
10,400 |
116,535 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-09-20 |
4 |
AS |
$27.96 |
$167,786 |
D/D |
(6,000) |
106,135 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-09-20 |
4 |
OE |
$6.00 |
$36,000 |
D/D |
6,000 |
112,135 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-09-26 |
4 |
OE |
$6.00 |
$31,200 |
D/D |
5,200 |
111,335 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-09-26 |
4 |
AS |
$22.54 |
$122,528 |
D/D |
(5,200) |
106,135 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-10-10 |
4 |
AS |
$21.94 |
$114,462 |
D/D |
(5,200) |
106,135 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-10-10 |
4 |
OE |
$6.00 |
$31,200 |
D/D |
5,200 |
111,335 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-10-24 |
4 |
AS |
$19.11 |
$99,351 |
D/D |
(5,200) |
106,135 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-10-24 |
4 |
OE |
$6.00 |
$31,200 |
D/D |
5,200 |
111,335 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-11-17 |
4 |
S |
$13.04 |
$46,170 |
D/D |
(3,541) |
102,594 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-11-20 |
4 |
S |
$11.26 |
$164,261 |
D/D |
(14,594) |
88,000 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-11-21 |
4 |
S |
$10.26 |
$191,555 |
D/D |
(18,665) |
69,335 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-12-07 |
4 |
S |
$11.85 |
$435,995 |
D/D |
(36,800) |
32,535 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2023-12-15 |
4 |
S |
$12.94 |
$428,180 |
D/D |
(32,535) |
0 |
0 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2024-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,661 |
6,161 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2024-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
11,557 |
17,718 |
0 |
- |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2024-05-29 |
4 |
B |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
0.01 |
% |
|
| GNLX |
Genelux Corp |
VP, Clinical Trial Operations |
• – – |
2024-06-24 |
4 |
S |
$2.12 |
$14,520 |
D/D |
(6,849) |
10,869 |
0 |
% |
|
24 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
